Last reviewed · How we verify
lumefantrine plus artemether
Lumefantrine and artemether work together as antimalarial agents that kill malaria parasites through distinct mechanisms involving heme detoxification and rapid parasite clearance.
Lumefantrine and artemether work together as antimalarial agents that kill malaria parasites through distinct mechanisms involving heme detoxification and rapid parasite clearance. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by other Plasmodium species susceptible to artemether-lumefantrine.
At a glance
| Generic name | lumefantrine plus artemether |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Antimalarial combination therapy |
| Target | Malaria parasite heme metabolism and hemozoin formation |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Artemether is a fast-acting artemisinin derivative that rapidly reduces parasite biomass and gametocyte levels, while lumefantrine is a longer-acting aminoalcohol that inhibits parasite growth by interfering with heme detoxification and hemozoin formation. Together, they provide both rapid symptom relief and sustained parasite suppression, reducing the risk of recrudescence and transmission.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Malaria caused by other Plasmodium species susceptible to artemether-lumefantrine
Common side effects
- Headache
- Fever
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Dizziness
- Asthenia/weakness
Key clinical trials
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) (PHASE2)
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria (PHASE4)
- OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa (PHASE4)
- CHILD (Child Health and Infection With Low Density) Malaria (NA)
- Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria (PHASE3)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lumefantrine plus artemether CI brief — competitive landscape report
- lumefantrine plus artemether updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI